Reverse aging History Timeline and Biographies

The establishment of Geron Corporation, a pioneer in telomerase research

Geron Corporation was established in 1998, focusing on telomerase technology. This research laid the groundwork for understanding how telomeres, protective caps on chromosomes, play a crucial role in cellular aging and the potential for Reverse aging therapies.

First evidence of cellular reprogramming in mice

In 2001, scientists demonstrated that introducing specific genes could reprogram adult cells back into a pluripotent state, suggesting a pathway for Reverse aging by potentially rejuvenating aged tissues and organs.

Discovery of induced pluripotent stem cells (iPSCs)

Shinya Yamanaka's groundbreaking work in 2006 revealed that mature cells could be reprogrammed into iPSCs, providing a powerful tool for studying Reverse aging and regenerative medicine, opening new avenues for cell therapy.

Telomere lengthening and its implications for Reverse aging

Research in 2013 demonstrated that lengthening telomeres in human cells could extend their lifespan, providing insights into potential therapies for Reverse aging by targeting the cellular aging process directly.

Launch of the first clinical trials for senolytics

In 2014, the first clinical trials for senolytic drugs began, which aim to selectively eliminate senescent cells. This approach holds promise for Reverse aging by improving tissue function and reducing age-related diseases.

Advancements in gene therapy for aging-related diseases

By 2016, significant progress was made in gene therapy targeting aging-related diseases, showcasing potential strategies for Reverse aging through genetic modifications to enhance healthspan and lifespan.

The emergence of the "young blood" hypothesis

In 2018, research suggested that factors in young blood could rejuvenate aged tissues, sparking interest in plasma transfusions and other methods as potential interventions for Reverse aging.

Development of NAD+ boosters

The discovery of NAD+ boosters in 2019 indicated that increasing levels of this critical coenzyme could improve cellular health and longevity, contributing to the broader field of Reverse aging research.

Launch of the first anti-aging therapeutics based on epigenetics

In 2020, the first anti-aging therapeutics targeting epigenetic changes were launched, marking a significant step in the application of epigenetics to Reverse aging and promote healthier aging processes.

Advancements in CRISPR technology for aging research

By 2021, CRISPR gene-editing technology was increasingly utilized in aging research, providing new methods to target genes associated with aging and potential strategies for Reverse aging interventions.

Breakthroughs in cellular senescence research

In 2022, significant breakthroughs in understanding cellular senescence provided insights into how targeting senescent cells could lead to effective Reverse aging therapies and improved healthspan.

FDA approval of first senolytic therapy

In 2023, the FDA approved the first senolytic therapy, marking a milestone in Reverse aging treatments aimed at improving health and longevity by clearing senescent cells from the body.

Emergence of comprehensive aging clocks

By 2024, the development of comprehensive biological aging clocks allowed researchers to measure biological age more accurately, facilitating the assessment of Reverse aging interventions and their effectiveness.